TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19999220

Group type: EXPERIMENTAL
Intervention: Sural nerve conduction studies measuring sensory nerve conduction velocity (SNCV) and sensory latency (SNSL)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Age-related impact on SNCV and SNSL
Number of subjects: 25
Study: 12854339

Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions
Number of subjects: 2720

Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions (high quality studies)
Number of subjects: 2720

Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions (low quality studies)
Number of subjects: 2720
Study: 10758471

Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 207
Study: 8885949

Group type: EXPERIMENTAL
Intervention: 20 ppm inhaled nitric oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy without inhaled nitric oxide
Number of subjects: 0
Study: 1570886

Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine/median approach
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine/paramedian approach
Number of subjects: 250

Group type: COMPARATOR
Intervention: paramedian approach (group II)
Number of subjects: 250
Study: 4091235

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 14
Study: 30895203

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26844723

Group type: EXPERIMENTAL
Intervention: Normal-dose therapy (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-dose therapy (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Normal-dose therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-dose therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Triple combination therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-dose and normal-dose groups
Number of subjects: 200
Study: 26440297

Group type: EXPERIMENTAL
Intervention: Uterine filling pressure of 30 mm Hg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Uterine filling pressure of 50 mm Hg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Uterine filling pressure of 80 mm Hg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 240
Study: 24649831

Group type: EXPERIMENTAL
Intervention: 6 weekly educational sessions promoting healthful nutrition and physical activity
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study: 22735037

Group type: EXPERIMENTAL
Intervention: Open-sea air dive to 30 msw for 30 min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Head-out water immersion for 30 min
Number of subjects: 15
Study: 20613476

Group type: EXPERIMENTAL
Intervention: Cosyntropin (1 mg intravenously)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study: 17625622

Group type: EXPERIMENTAL
Intervention: Xeno III with Dyract AP (Dentsply)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop with Z2000 (3M Espe)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 15702438

Group type: EXPERIMENTAL
Intervention: Regular pulsatile insulin release pattern
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Irregular pulse frequency insulin release pattern
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Irregular pulse amplitude insulin release pattern
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Very fast-pulsatile insulin release pattern
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Constant insulin infusion
Number of subjects: 10
Study: 12083474

Group type: EXPERIMENTAL
Intervention: Orally administered lorazepam before surgery
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Listening to relaxing music through headphones before surgery
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Walking to the operating room
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Listening to relaxing music through headphones during surgery
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral sedation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Regional local anesthesia
Number of subjects: 144

Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 144
Study: 10431116

Group type: EXPERIMENTAL
Intervention: 20 mg of zinc (group Z)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 20 mg of zinc with additional vitamins and minerals (group Z+VM)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 412
Study: 8588794

Group type: EXPERIMENTAL
Intervention: 5% carbohydrate‐electrolyte drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4% carbohydrate‐electrolyte drink containing 1% glycerol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 0
Study: 2699176

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthetic with supplementary general anaesthetic (group I)
Number of subjects: 14

Group type: COMPARATOR
Intervention: General anaesthetic as usual (group II)
Number of subjects: 14
Study: 778989

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (4.55 g daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Micro-encapsulated aspirin (4.50 g daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Micro-encapsulated aspirin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both aspirin preparations
Number of subjects: 48
Study: 30706087

Group type: EXPERIMENTAL
Intervention: Autologous impaction bone grafting
Number of subjects: 98

Group type: COMPARATOR
Intervention: Traditional uncemented primary THR technique
Number of subjects: 98
Study: 28684845

Group type: EXPERIMENTAL
Intervention: Multiple fresh fecal microbiota transplants (FMT)
Number of subjects: 25
Study: 26283236

Group type: EXPERIMENTAL
Intervention: Dronabinol 5 mg twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 23392450

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 200
Study: 21762974

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omalizumab 600 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omalizumab 75 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19668245

Group type: EXPERIMENTAL
Intervention: Mood-stabilizing drug or neuroleptic in severe cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium or anticonvulsant for prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition of brief outbursts of excessive emotion (especially anger)
Number of subjects: 0
Study: 16965864

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 56
Study: 15712502

Group type: EXPERIMENTAL
Intervention: Regular training plus the Wingate 5-step mental training program (adapted for swimming)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular training plus relaxing activities
Number of subjects: 40
Study: 12418596

Group type: EXPERIMENTAL
Intervention: Salbutamol delivered via HFA134a pMDI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol delivered via Turbuhaler
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9507989

Group type: EXPERIMENTAL
Intervention: Low DHA (0.75 g/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High DHA (1.50 g/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (DHA-free)
Number of subjects: 100
Study: 7883122

Group type: EXPERIMENTAL
Intervention: Hexokinase II gene analysis using PCR and SSCP screening
Number of subjects: 59
Study: 1982761

Group type: EXPERIMENTAL
Intervention: Broxaterol (100, 200, 400 micrograms)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol (100, 200, 400 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 360366

Group type: EXPERIMENTAL
Intervention: Ancrod treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 42
Study: 30257549

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg if LDL-C ≥ 70 mg/dL at week 8)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 28352063

Group type: EXPERIMENTAL
Intervention: Erythromycin infusion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Gastric lavage
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Erythromycin + gastric lavage
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study: 25711435

Group type: EXPERIMENTAL
Intervention: Early invasive strategy post-fibrinolysis
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1059
Study: 23343951

Group type: EXPERIMENTAL
Intervention: Pterygium extended removal followed by extended conjunctival transplant
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control eye (no surgery)
Number of subjects: 395
Study: 21184067

Group type: EXPERIMENTAL
Intervention: Combined epidermal and dermal replacement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin transplantation supplemented with Matriderm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional full-thickness skin transplantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retroauricular perichondrodermal composite grafts
Number of subjects: 30
Study: 19996038

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Talking Control (TC)
Number of subjects: 204
Study: 17726361

Group type: EXPERIMENTAL
Intervention: Multidimensional training program including moderate resistance exercise and balance exercise twice weekly for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (n=33)
Number of subjects: 65
Study: 15479135

Group type: EXPERIMENTAL
Intervention: Hypoxemic congenital heart diseases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normoxemic congenital heart diseases
Number of subjects: 0
Study: 11808868

Group type: EXPERIMENTAL
Intervention: Thiocolchicoside, 4 mg ampoules (test formulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Muscoril, 4 mg ampoules (reference formulation)
Number of subjects: 12
Study: 10101929

Group type: EXPERIMENTAL
Intervention: Well metabolically controlled diabetic patients (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Poorly metabolically controlled diabetic patients (group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 50
Study: 8089241

Group type: EXPERIMENTAL
Intervention: Mouthwash products (5 different types)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Chlorhexidine rinse product (positive control)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CPC rinses (2 types)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer, essential oil/phenolic products
Number of subjects: 14
Study: 30321767

Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM) for 6 weeks (3 days a week, 10 times a day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No ESM (control group)
Number of subjects: 79
Study: 28573716

Group type: EXPERIMENTAL
Intervention: Experimental group (category labels A and B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no category labels, stimuli labelled S1-S6)
Number of subjects: 0
Study: 26406234

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Strength Training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 31
Study: 23349486

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 10 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 21 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 21306296

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 0
Study: 19928571

Group type: EXPERIMENTAL
Intervention: Ascorbic acid and emoxypine during the first 10 days of standard chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emoxypine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study: 16987112

Group type: COMPARATOR
Intervention: Growth hormone (GH) withdrawal for 3 months
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: HDQoL questionnaire
Number of subjects: 157
Study: 12820283

Group type: EXPERIMENTAL
Intervention: Intravaginal microbicide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right-truncated models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture models
Number of subjects: 0
Study: 10860211

Group type: EXPERIMENTAL
Intervention: Single blind placebo 'run-in' or 'washout' periods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10166596

Group type: EXPERIMENTAL
Intervention: Feedback plus reminders
Number of subjects: 2409

Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 2409
Study: 8439024

Group type: EXPERIMENTAL
Intervention: 25 micrograms/kg intravenous alfentanil
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 50 micrograms/kg intravenous alfentanil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (orthopedic patients)
Number of subjects: 32
Study: 3730521

Group type: EXPERIMENTAL
Intervention: Intravenous bromopride 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral bromopride 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular bromopride 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral bromopride 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral bromopride 30 mg
Number of subjects: 0
Study: 30221597

Group type: EXPERIMENTAL
Intervention: 100 mg of enteric-coated aspirin
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 26806605

Group type: EXPERIMENTAL
Intervention: SQ BNP 10 µg/kg, twice-daily for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23733278

Group type: EXPERIMENTAL
Intervention: CAG with 10-0 monofilament nylon sutures (group I)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CAG with in-situ blood coagulum (group II)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (group I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 32
Study: 22704398

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 4047
Study: 20091934

Group type: EXPERIMENTAL
Intervention: Continuous infusion of epidural local anesthetics plus intravenous opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous opioids only
Number of subjects: 0
Study: 18356603

Group type: EXPERIMENTAL
Intervention: Continuous ART (Arm A)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Continue for 9 weeks, then STI (Arm B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Two cycles of IL‐2 while on ART, then STI (Arm C)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: IL‐2 intervention
Number of subjects: 86
Study: 16157797

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide 3 times daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: 0.25% timolol maleate gel-forming solution once daily plus placebo twice daily (control)
Number of subjects: 122
Study: 11773507

Group type: EXPERIMENTAL
Intervention: palmolein diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: oleic acid sunflower oil diet
Number of subjects: 14
Study: 9927004

Group type: EXPERIMENTAL
Intervention: High-intensity strength-training program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 100
Study: 7570396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic treatment
Number of subjects: 0
Study: 2178380

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2466
Study: 444661

Group type: EXPERIMENTAL
Intervention: BCMP (melphalan, cyclophosphamide, and carmustine) with tapering course of prednisone
Number of subjects: 252

Group type: COMPARATOR
Intervention: MP (oral melphalan) with tapering course of prednisone
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: BCMP (for poor-risk group)
Number of subjects: 252

Group type: COMPARATOR
Intervention: MP (for poor-risk group)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: BCMP (for good-risk group)
Number of subjects: 252

Group type: COMPARATOR
Intervention: MP (for good-risk group)
Number of subjects: 252
Study: 31166864

Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shockwave therapy (ESWT) with standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment with standard care
Number of subjects: 0
Study: 28927211

Group type: EXPERIMENTAL
Intervention: Adherus Dural Sealant
Number of subjects: 250

Group type: COMPARATOR
Intervention: DuraSeal Dural Sealant System
Number of subjects: 250
Study: 25339110

Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stents (Resolute zotarolimus-eluting or Xience V everolimus-eluting stents)
Number of subjects: 674
Study: 24481143

Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripsy (PL)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Holmium: YAG laser lithotripsy (LL)
Number of subjects: 133
Study: 22956828

Group type: EXPERIMENTAL
Intervention: Auditory memory load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acoustic degradation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined highest load and most severe degradation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha oscillatory dynamics during stimulus-free delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Source localization of alpha power
Number of subjects: 0
Study: 19542011

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate/higher monounsaturated fat diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Higher carbohydrate/lower fat diet
Number of subjects: 30
Study: 17679749

Group type: EXPERIMENTAL
Intervention: Gabapentin (400 mg) administered twice weekly after HD sessions for four weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo administered twice weekly after HD sessions for four weeks
Number of subjects: 34
Study: 15457363

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression devices (IPC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 120
Study: 11514042

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroid (Pulmicort Turbuhaler)
Number of subjects: 7240

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 7240
Study: 9271766

Group type: EXPERIMENTAL
Intervention: Individualized exercise training at the gas exchange threshold (GET)
Number of subjects: 14
Study: 8290741

Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg nocte
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3125773

Group type: EXPERIMENTAL
Intervention: Intermittent rectal diazepam
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Continuous oral sodium valproate
Number of subjects: 69

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 69
Study: 31135812

Group type: EXPERIMENTAL
Intervention: Nonfasting lipid levels
Number of subjects: 8270

Group type: COMPARATOR
Intervention: Fasting lipid levels
Number of subjects: 8270

Group type: EXPERIMENTAL
Intervention: Nonfasting lipid levels (primary prevention group)
Number of subjects: 8270

Group type: COMPARATOR
Intervention: Fasting lipid levels (primary prevention group)
Number of subjects: 8270

Group type: EXPERIMENTAL
Intervention: Nonfasting and fasting lipid levels
Number of subjects: 8270
Study: 29525281

Group type: EXPERIMENTAL
Intervention: LetiFend® vaccine
Number of subjects: 549
Study: 27397444

Group type: EXPERIMENTAL
Intervention: Oral Vitamin C (500 mg) twice daily for 7 days prior to surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antacid tablet as placebo twice daily for 7 days prior to surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antacid tablet as placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Oral Vitamin C (500 mg)
Number of subjects: 70
Study: 24356524

Group type: EXPERIMENTAL
Intervention: Chest wall strapping (CWS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unrestricted control
Number of subjects: 20
Study: 22637204

Group type: EXPERIMENTAL
Intervention: NeoCart
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 30
Study: 20117571

Group type: EXPERIMENTAL
Intervention: Micro intervention (monthly home visits by a promotora over a 7-month period plus monthly mailed newsletters)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Macro-only condition
Number of subjects: 811

Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 811